MSN: Abemaciclib + Endocrine Therapy Improves Survival in HR-Positive, HER2-Negative Early Breast Cancer Abemaciclib + Endocrine Therapy Improves Survival in HR-Positive, HER2-Negative Early Breast Cancer The New England Journal of Medicine: Imlunestrant with or without Abemaciclib in Advanced Breast Cancer Nasdaq: Lilly to present new clinical data for Verzenio (abemaciclib) and multiple novel pipeline programs at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting Primary overall survival analysis from the Phase 3 monarchE study of Verzenio (abemaciclib) in HR+HER2-, node-positive, high-risk early breast cancer to be presented as a late-breaking oral ... Lilly to present new clinical data for Verzenio (abemaciclib) and multiple novel pipeline programs at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting ascopubs.org: Erratum: Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial Erratum: Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE ...
